Stable pharmaceutical formulations for treating internal bowel syndrome containing isoxazole derivatives
AssigneeRoberts Laboratories Inc.
InventorPhilip C. Lang
Life of this patent
Estimating the term…
Loading patent…
AssigneeRoberts Laboratories Inc.
InventorPhilip C. Lang
Estimating the term…
Chemically stable pharmaceutical formulations comprising a therapeutically effective amount of a material of formula I are provided which formulations contain a stabilizer system comprising an organic carboxylic acid containing more than 1 carboxylic acid group and an antioxidant. The preferred organic carboxylic acid is citric acid and the preferred antioxidants are ascorbic acid and butylated hydroxytoluene, which antioxidants are preferred to be used in admixture. The chemically stable pharmaceutical formulations are particularly useful for treating Irritable Bowel Syndrome (IBS) in mammals and comprises administering to the mammal needing treatment an effective dose of the above chemically stable pharmaceutical formulation. The stabilizer system is also effective for use in other pharmaceutical formulations containing active ingredients having oxidizable groups such as amino, phenolic, hydryoxyl amino, aldehyde, unsaturated compounds, sulfoxide, sulfone and mercapto. The preferred Formula I compound is as follows: ##STR1## wherein R and R.sup.1 are propyl; R.sub.2 and R.sub.3 are hydrogen; Y is CH.sub.2 and the compound is an HCl salt.
A chemically stable pharmaceutical composition comprising:
A method of treating Irritable Bowel Syndrome in mammals comprises administering to the mammal in a need of treatment an effective dose of a chemically stable pharmaceutical composition comprising:
A stabilizer system for a pharmaceutical composition containing a therapeutical amount of a material corresponding to a compound of formula I:
Dependencies are inferred from the claim text.